Citadel Advisors’s Impact BioMedical IBO Stock Holding History
Bought
Maintained
Sold
Other funds holding IBO
Citadel Advisors's IBO Position: Q2 2026 in Review
Citadel Advisors opened a new position in Impact BioMedical (IBO) in Q2 2026: 3,928 shares worth $22.8K. The stake represents ﹤0.01% of the portfolio and ranks #13376 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IBO as recently as Q1 2025.
Citadel Advisors first reported a position in IBO in Q1 2025 and has held it in 2 quarters since. The position peaked at $52.5K in Q1 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q2 2026.
- Citadel Advisors held 3,928 shares of Impact BioMedical worth $22.8K as of Q2 2026.
- Impact BioMedical was a new Citadel Advisors position in Q2 2026.
- Impact BioMedical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13376 holding.
- Citadel Advisors first reported a position in Impact BioMedical in Q1 2025 and has held it in 2 quarters since.
- Citadel Advisors's Impact BioMedical position peaked at $52.5K in Q1 2025.
- 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.